Research Article: PD-L1 targeted peptide demonstrates potent antitumor and immunomodulatory activity in cancer immunotherapy
Abstract:
Background: In recent years, immunotherapy has been emerging as a promising alternative therapeutic method for cancer patients, offering potential benefits. The expression of PD-L1 by tumors can inhibit the T-cell response to the tumor and allow the tumor to evade immune surveillance. To address this issue, cancer immunotherapy has shown promise in disrupting the interaction between PD-L1 and its ligand PD-1.
No summary available.